Prosecution Insights
Last updated: November 04, 2026
Application No. 19/407,845

INHALATION FORMULATION FOR TREATING IPF DISEASE AND PREPARATION METHOD THEREFOR

Final Rejection §103
Filed
Dec 03, 2025
Priority
Sep 07, 2023 — CN 202311151725.6 +1 more
Examiner
GHALI, ISIS A D
Art Unit
1611
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Suzhou Inhal Pharma Co. Ltd.
OA Round
2 (Final)
28%
Grant Probability
At Risk
3-4
OA Rounds
3y 5m
Est. Remaining
70%
With Interview

Examiner Intelligence

Grants only 28% of cases
28%
Career Allowance Rate
238 granted / 853 resolved
-32.1% vs TC avg
Strong +42% interview lift
Without
With
+41.6%
Interview Lift
resolved cases with interview
Typical timeline
4y 4m
Avg Prosecution
30 currently pending
Career history
903
Total Applications
across all art units

Statute-Specific Performance

§101
1.1%
-38.9% vs TC avg
§103
51.2%
+11.2% vs TC avg
§102
7.4%
-32.6% vs TC avg
§112
24.9%
-15.1% vs TC avg
Black line = Tech Center average estimate • Based on career data from 853 resolved cases

Office Action

§103
DETAILED ACTION The receipt is acknowledged of applicant’s amendment filed 08/27/2026. Claims 1-20 previously presented. Claim 13 has been canceled and claims 21-30 have been added. Claims are 1-12 and 14-30 are pending. Claims 4-9 and 14-20 are withdrawn from further consideration Election was made without traverse in the reply filed on 05/07/2026. Claims 1-3, 10-12 and 21-30 are examined on the merits. Rejections and/or objections not reiterated from previous office actions are hereby withdrawn. The following rejections and/or objections are either reiterated or newly applied. They constitute the complete set presently being applied to the instant application. Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Claim Rejections - 35 USC § 103 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention. Claims 1-3, 10-12, and 21-30 are rejected under 35 U.S.C. 103 as being unpatentable over the combination of Turkyilmaz et al. (WO 2020/055357, IDS filed 12/03/2025), Sreedharala (WO 2021/214789, previously cited on PTO 892, and copy was provided), and the article to Cutolo et al. (“Apremilast interferes with the TGFβ1-induced transition of human skin fibroblasts into profibrotic myofibroblasts: in vitro study”, previously cited on PTO 892, and copy was provided). Applicant Claims Claim 1 is directed to a pharmaceutical formulation comprising an active drug selected from the group consisting of apremilast, ibudilast, crisaborole, and difamilast, wherein the active drug has particle size D90 ranging from about 1 µm to about 10 µm, and wherein the pharmaceutical formulation is an inhalation formulation that has a greater bioactivity for the treatment of an idiopathic pulmonary fibrosis (IPF) in a subject in need thereof as compared to bioactivity of an oral formulation, as characterized by decreased level of malondialdehyde (MDA) or hydroxyproline (HYP) in lung of the subject. Determination of the Scope and Content of the Prior Art (MPEP §2141.01) Turkyilmaz teaches dry powder inhalation formulation administered by means of inhaler and free from lubricant and surfactants (abstract). The reference teaches dry powder inhaler (DPI) comprises PD-4 inhibitors particles and carrier particles that controls fluidity of the drug and ensures that the drug reaches to the lung is accurate and consistent. The dry powder particles are adhered to the carrier homogeneously and adhesion is quite strong so the drug cannot detach from the carrier particles (page 3, lines 30-37). PD-4 inhibitors treat lung fibrosis (page 5, lines 30-33). Example of PD-4 inhibitors is ibudilast (page 6, lines 27-29). The particle size of the powder of PD-4 inhibitor is between 0.1-50 µm (page 7, lines 1-4). Mean particle size of the powder ensures the drug reaches the alveoli (page 7, lines 14-15). The carrier preferably lactose monohydrate having particle size between 10-100 µm (page 7 line 28 till page 8, line 7). The drug present in the formulation in amount 1-40%, and the rest is lactose (page 9, lines 20-25; examples; claims), i.e. lactose is from 60-99% of the formulation. Lactose is a homogeneous mixture of fine particles and coarse particles. The fine lactose particles have mean particle size lower than 100 µm, preferably between 0.1 and 50 µm, and most preferably 0.5-25 µm. Fine carrier particles help the active agent to reach the lung easier and in higher doses (page 3, line 36 till page 4 line 5; page 7 lines 33-36; page 8, lines 1-7, 16-22). The reference teaches fine particle fraction (FPF) above 15%. The amount of fine lactose is in the range of 1-40%, and more preferably 3-15% (page 9, lines 15-25; examples). Ascertainment of the Difference Between Scope the Prior Art and the Claims (MPEP §2141.012) While Turkyilmaz teaches treating lung fibrosis using dry powder inhaler comprising PD-4 inhibitors to treat lung fibrosis, the reference does not exemplify the claimed PD-4 inhibitors, and does not teach treating intrapulmonary fibrosis (IPF), in particular, as claimed by claim 1. Sreedharala teaches apremilast administered intra-pulmonary by dry powder inhaler (page 15, last paragraph till last paragraph page 26). The size of the powder particles range from 100 nm to 5000 nm (page 17, 2nd full paragraph) i.e. 1-5 µm. Cutolo teaches phosphodiesterase-4 inhibitors (PD-4), and apremilast in particular is of interest in treating fibrosis in IPF patients because apremilast is efficient because it interferes with fibrosis primely in early phases of the disease (see the entire document, and in particular abstract; and page 3836, right column). Finding of Prima Facie Obviousness Rational and Motivation (MPEP §2142-2143) Therefore, it would have been obvious to one having ordinary skill in the art before the effective filing date of the present invention to provide inhalation formulation comprising dry powder of PD-4 inhibitors having the claimed mean particle sizes to treat lung fibrosis as taught by Turkyilmaz, and use apremilast in the composition to treat IPF as taught by Sreedharala and Cutolo. One would have been motivated to do so because Sreedharala teaches suitability of PD-4 to be administered as dry powder inhalation intra pulmonary, and because Cutolo teaches PD-4 inhibitors are of interest and efficient to treat IPF because PD-4 inhibitors interfere with fibrosis primely in early phases of the disease. One would reasonably expect formulating dry inhaler formulation comprising apremilast of the claimed particles size that effectively treats IPF in its early phase. Regarding the particle size of the drug as claimed by claim 1 of 1-10 µm, and 4.6 µm as claimed by claim 29, Turkyilmaz teaches particle size of the powder of PD-4 is between 0.1-50 µm that overlaps with the claimed particle sizes of 1-10 µm of the drug. In the case where the claimed ranges "overlap or lie inside ranges disclosed by the prior art" a prima facie case of obviousness exists. See MPEP 2144.05 [R-5]. Regarding the limitation of claim 1 of “formulation that has a greater bioactivity for the treatment of an idiopathic pulmonary fibrosis (IPF) in a subject in need thereof as compared to bioactivity of an oral formulation, as characterized by decreased level of malondialdehyde (MDA) or hydroxyproline (HYP) in lung of the subject”, this is a function of used drug that is inseparable from the drug. Further comparing the bioactivity is an in vivo test and not part of the claimed pharmaceutical formulation. Regarding apremilast claimed by claims 2, 24 and 29, apremilast is taught by both Sreedharala and Cutolo. In any event, applicants failed to show unexpected results obtained from using apremilast over any other PD-4 drugs. Regarding the elected species of “dry powder inhaler” claimed by claims 3, 23 and 25, it is taught by Turkyilmaz and Sreedharala. Regarding carrier claimed by claim 10 and lactose as claimed by claim 11, this is taught by Turkyilmaz. Regarding the ratio of the drug to the carrier as claimed by claim 12, Turkyilmaz teaches the drug can be 1-40%, and hence the lactose carrier forms 60-99% of the powder formulation that falls within the claimed ratio of 5-99% to 99-1%. In the case where the claimed ranges "overlap or lie inside ranges disclosed by the prior art" a prima facie case of obviousness exists. See MPEP 2144.05 [R-5]. Regarding claims 21, 22 and 25 that the inhalation formulation has a fine particle fraction (FPF) percentage of about 16% to about 50%, 16.9-46.8%, and 46.8%, respectively, Turkyilmaz teaches FPF above 15% that overlaps with the claimed ranges. Note the term “about” of the claims that permits 10% above or below of the claimed range, unless otherwise defined in the specification. Regarding the particle size of the carrier of 3-200 µm as claimed by claim 26, Turkyilmaz teaches particle size of lactose is between 10-100 µm that overlaps with the claimed particle sizes of lactose. In the case where the claimed ranges "overlap or lie inside ranges disclosed by the prior art" a prima facie case of obviousness exists. See MPEP 2144.05 [R-5]. Regarding claim 27 that the formulation comprises about 20% apremilast in the dry powder formulation, Turkyilmaz teaches 1-40% PD-4 inhibitors in the inhalation formulation that embraces the claimed amount. In the case where the claimed ranges "overlap or lie inside ranges disclosed by the prior art" a prima facie case of obviousness exists. See MPEP 2144.05 [R-5]. In any event, one having ordinary skill in the art would have determined the desired amount of the drug based on individual patient’s condition. Regarding lactose monohydrate claimed by claims 28 and 30, and its amount of about 80% as claimed by claim 28, and its particle size of 7.5 µm as claimed by claim 30, Turkyilmaz teaches lactose monohydrate and teaches amount of the carrier of 60-99% that embraces the claimed amount, and further teaches lactose particles size of less than 100 µm for the fine particles and preferably 0.5-25 µm that embraces the claimed size. In the case where the claimed ranges "overlap or lie inside ranges disclosed by the prior art" a prima facie case of obviousness exists. See MPEP 2144.05 [R-5]. Absent any evidence to the contrary, and based upon the teachings of the prior art, there would have been a reasonable expectation of success in practicing the instantly claimed invention. Therefore, the invention as a whole would have been prima facie obvious to one of ordinary skill in the art before the effective filing date of the present invention. Response to Arguments Applicant's arguments filed 08/27/2026 have been fully considered but they are not persuasive. Applicants argue that Turkyilmaz in view of Cutolo does not teach or suggest all the claimed elements for a finding of obviousness. Turkyilmaz never discloses an inhalation formulation that has an active drug with a particle size D90 ranging from about 1 µm to about 10 µm for the treatment of IPF, particularly a formulation that results in a greater bioactivity than its oral formulation in IPF treatment. Although Cutolo discloses that PDE4 inhibitors may be of interest in fibroproliferative and fibrotic diseases, it does not provide any formulation that would result in a greater bioactivity in treating IPF disease than a corresponding oral formulation. In response to this argument. Applicant’s attention is directed to the scope of the present invention that is directed to a composition, and all the elements of the claimed composition are taught by combination of the cited references. Turkyilmaz teaches the particle sizes of preferably 0.5-25 µm that overlap with the claimed particle size of 1-10 µm. Using PDE-4 inhibitors for treating IPF was known before the effective filing date of the present invention as taught by Cutolo. Administering PDE-4 inhibitors as dry powder inhalation formulation was also known and taught by both Turkyilmaz and Sreedharala. If Turkyilmaz or Cutolo was to teach all the elements of the claims, the reference would have been considered for anticipation. One cannot attack the references individually wherein obviousness is based on combination of references. Further, motivation to combine the cited references exists, and reasonable expectation to achieve the present invention was presented. Applicants argue that the proposed combination of Turkyilmaz and Cutolo would change Turkyilmaz's principle of operation. Specifically, Turkyilmaz teaches pulmonary delivery of a dry powder inhalation formulation that contains a PDE-4 inhibitor and lactose carrier for the treatment of COPD, asthma, chronic bronchitis, and cystic fibrosis. Turkyilmaz further discloses use of the PDE-4 inhibitor for downregulating inflammatory response. Cutolo relates to teachings of apremilast for reducing TGFß1-induced fibroblast-to-myofibroblast transition in skin fibroblasts, a completely different mechanism of action from that disclosed in Turkyilmaz. A skilled artisan would not have combined Turkyilmaz and Cutolo because the proposed combination would change Turkyilmaz's disclosed mechanism of action. The examiner respectfully disagrees with this argument because present claims are directed to a product, and all the elements of the claimed product are taught by combination of the cited references. Both Turkyilmaz and Cutolo use PDE-4 inhibitors, and Turkyilmaz administered the drug by dry powder inhalation to treat lung conditions including fibrosis, and Cutolo used the same drugs to treat IPF. Therefore, one having ordinary skill in the art desired to treat IPF would be motivated from the teachings of both references to administer the drugs by inhalation to treat IPF. The mechanism of action of the drugs is inseparable from the drug, and same compound cannot have mutually exclusive characteristics. It has been decided by the Courts that even in a case where the reference does not teach the same use of the composition, the two different intended uses are not distinguishable in terms of the composition, see In re Thuau, 57 USPQ 324; Ex parte Douros, 163 USPQ 667; and In re Craige, 89 USPQ 393. In any event, the intended use of the claimed composition does not impart patentability to the claims that are directed to composition. Applicants argue that the combination of Turkyilmaz and Cutolo provides no teaching or guidance for a person of skill in the art to arrive at the claimed subject matter with a reasonable expectation of success. Treatment of an IPF mouse model with the formulation alleviated oxidative damage and reduced pulmonary fibrosis, and reduced expression levels of fibrosis biomarkers such as MDA and HYP to a greater extent than the oral formulation. FIG. 4 and FIG. 9 of the instant application. These results suggest a greater bioactivity of the formulation for IPF treatment as compared to the oral formulation. Such effects have not been shown in either Turkyilmaz or Cutolo. Turkyilmaz's inhalers are formulated based on active-drug and carrier particle-size parameters that are irrelevant to D90 particle size as disclosed in the current application for the treatment of IPF diseases. As such, a person would be left with limitless alternatives and no guidance to arrive at the claimed subject matter with a reasonable expectation of success. In response to applicant’s argument that there is no teaching, suggestion, or motivation to combine the references, the examiner recognizes that obviousness may be established by combining or modifying the teachings of the prior art to produce the claimed invention where there is some teaching, suggestion, or motivation to do so found either in the references themselves or in the knowledge generally available to one of ordinary skill in the art. See In re Fine, 837 F.2d 1071, 5 USPQ2d 1596 (Fed. Cir. 1988), In re Jones, 958 F.2d 347, 21 USPQ2d 1941 (Fed. Cir. 1992), and KSR International Co. v. Teleflex, Inc., 550 U.S. 398, 82 USPQ2d 1385 (2007). In this case, motivation to combine the references exists with reasonable expectation to achieve the present invention, as set forth in this office action. It should be noted that the motivation to combine references can be different from the ones set forth by Applicant. That is, as long as motivation exists to combine the elements, the problem to be solved does not have to involve the same reason. Any properties applicants achieved, e.g. alleviation of oxidative damage and reduction of pulmonary fibrosis, and reduction of expression levels of fibrosis biomarkers such as MDA and HYP to a greater extent than the oral formulation, are expected from the prior art combination especially treatment of IPF that is achieved by the prior art using PDE-4. Turkyilmaz teaches dry inhaler formulation comprising PDE-4 inhibitors drugs and lactose as claimed, and having the claimed particle size to deliver the drugs to the lung as claimed. The secondary reference, Sreedharala, teaches the claimed PDE-4 inhibitors administered by as dry inhaler, and Cutolo teaches PDE-4 inhibitors treats IPF. Therefore, it is obvious that administering PDE-4 inhibitors as powder by dry inhaler would treat IPF. Finally, obviousness does not require absolute predictability of success all that is required is a reasonable expectation of success. See In re Kubin, 561 F.3d at 1360. The Court has held that "the test of obviousness is not express suggestion of the claimed invention in any or all of the references but rather what the references taken collectively would suggest to those of ordinary skill in the art presumed to be familiar with them." See In re Rosselet, 146 USPQ 183, 186 (CCPA 1965). "There is no requirement (under 35 USC 103(a)) that the prior art contain an express suggestion to combine known elements to achieve the claimed invention. Rather, the suggestion to combine may come from the prior art, as filtered through the knowledge of one skilled in the art." Motorola, Inc. V. Interdigital Tech. Corp., 43 USPQ2d 1481, 1489 (Fed. Cir. 1997). An obviousness determination is not the result of a rigid formula disassociated from the consideration of the facts of a case. Indeed, the common sense of those skilled in the art demonstrates why some combinations would have been obvious where others would not. See KSR Int'l Co. V. Teleflex Inc., 82 USPQ2d 1385 (U.S. 2007) ("The combination of familiar elements according to known methods is likely to be obvious when it does no more than yield predictable results."). Conclusion Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Isis A D Ghali whose telephone number is (571)272-0595. The examiner can normally be reached Monday through Friday, 8:30 AM to 5:00 PM EST. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Bethany Barham can be reached at 571-272-6175. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /ISIS A GHALI/Primary Examiner, Art Unit 1611
Read full office action

Prosecution Timeline

Dec 03, 2025
Application Filed
May 29, 2026
Non-Final Rejection mailed — §103
Aug 27, 2026
Response Filed
Sep 21, 2026
Final Rejection mailed — §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12778807
Dressing Device for use with a Cannula or a Catheter
4y 7m to grant Granted Nov 03, 2026
Patent 12781028
POLYMER COMPOSITION AND PREPARATION METHOD THEREFOR
3y 0m to grant Granted Nov 03, 2026
Patent 12766123
COMPOSITIONS OF TRIGLYCERIDES AND USES THEREOF
1y 9m to grant Granted Oct 20, 2026
Patent 12766124
COMPOSITIONS OF TRIGLYCERIDES AND USES THEREOF
1y 9m to grant Granted Oct 20, 2026
Patent 12734267
METHOD FOR MANUFACTURING MEDICAL MATERIAL OF WHICH HEMOSTASIS AND DEGRADATION RATES ARE CONTROLLABLE, AND MEDICAL MATERIAL MANUFACTURED THEREBY
2y 9m to grant Granted Sep 15, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
28%
Grant Probability
70%
With Interview (+41.6%)
4y 4m (~3y 5m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 853 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month